STAGE II LUNG CANCER AJCC V8

This study is testing whether adding an immunotherapy drug (atezolizumab) to a precise form of radiation therapy works better than radiation alone for people with early-stage, non-small cell lung cancer who cannot have surgery. The goal is to see if the combination helps patients…

This study is testing whether a lung cancer immunotherapy drug can be safely and effectively given at home by a visiting nurse, with most doctor visits done remotely via video call. It involves patients with non-small cell lung cancer who are eligible for the drug atezolizumab. T…

This study is comparing two standard ways to treat small lung tumors: a minimally invasive procedure that uses microwave energy to heat and destroy the tumor, and a small surgery to cut it out. Researchers want to see which method is safer, more effective at keeping the cancer fr…

This study is testing a two-part treatment for patients with stage II or III non-small cell lung cancer who are not healthy enough for standard surgery or chemo-radiation. First, patients receive a shorter, more intense course of radiation. Then, they receive an immunotherapy dru…

This early-stage study is testing whether two immunotherapy drugs (ipilimumab and nivolumab) can be safely combined with radiation therapy for patients with stage II or III non-small cell lung cancer. The goal is to see if this combination helps the immune system attack the cance…

This large study is testing whether adding an immunotherapy drug (atezolizumab) to standard chemotherapy and radiation treatment helps people with early-stage small cell lung cancer live longer. About 544 patients will be randomly assigned to receive either the standard treatment…

This early-stage study is testing a new drug called NBTXR3, given as an injection directly into lung tumors, along with radiation therapy. The goal is to find the safest dose and see if the drug helps the radiation work better to kill cancer cells in people whose non-small cell l…

This large study is testing if adding a new pill (AZD6738) to a standard immunotherapy drug (durvalumab) is better at keeping cancer from coming back in people with certain stages of non-small cell lung cancer. It's for patients who have already had chemotherapy and surgery, but …

This study is testing whether the immunotherapy drug pembrolizumab can prevent lung cancer in people at high risk. It includes people with suspicious lung nodules that haven't grown or shrunk, and people who've had early-stage lung cancer treated before. Participants receive the …

This study is testing a simple, easy-to-understand conversation tool designed to help people with non-small cell lung cancer. The tool aims to improve how patients and doctors talk about treatment options, making the decision-making process clearer and less stressful. Researchers…

This study is testing a telehealth program designed to help people who have finished treatment for early-stage lung or colorectal cancer. It compares a special coaching program that teaches self-management skills to standard educational materials. The goal is to see if the coachi…

This study is testing an online support program designed to help women with lung cancer feel better emotionally and manage their symptoms. Participants are assigned to either a group learning mindfulness and coping skills or a group receiving educational information about lung ca…

This study aims to create a tool to predict which cancer patients are most likely to develop nerve damage (like tingling or numbness in hands and feet) from a common class of chemotherapy drugs called taxanes. Researchers will follow over 1,300 patients with breast, lung, or ovar…